Liver cancer responds to Issels Integrative Immunotherapy
SCOTTSDALE, Ariz., Jan. 21, 2014 /PRNewswire/ -- The liver performs many vital tasks, including digestive and hormonal functions. As the body's main detoxification system, it is susceptible to developing secondary cancers from circulating cancer cells.
To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/65144-issels-integrative-immunotherapy-liver-cancer-treatment-stage-four
Primary liver cancer (hepatocellular carcinoma) arises from liver cells and has the worst prognosis among all liver cancers, with a relative survival rate of 15%, according to the American Cancer Society.
As with many cancers, highly toxic standard treatments can only be given sparingly for liver cancers, highlighting the importance of the non-toxic Issels Integrative Immunotherapy. While several leading Cancer Centers in the U.S. and abroad have only begun using immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
In 1951, Dr. Josef M. Issels, MD founded the world's first hospital specializing in integrative oncology and achieved documented complete long-term remissions of standard therapy-resistant cancers. In view of his expertise, Dr. Issels was invited to serve as an expert member of the German Federal Government Commission in the Fight against Cancer from 1981 until his retirement in 1987.
Issels Integrative Immunotherapy distinguishes itself decisively from mere vaccine administration. The Issels strategy integrates specific autologous cancer vaccines, such as Dendritic Cell Vaccine, as well as autologous Lymphokine-Activated Killer (LAK) Cells and activated autologous Natural Killer (NK) Cells, which work on the cell-mediated level of the immune system, into a comprehensive immunobiologic core treatment. This core treatment addresses the tumor microenvironment and the body's complex defense mechanisms, enhancing the efficacy of vaccine and cell therapies.
The Issels medical team brings decades of expertise tailoring integrative immunotherapy for each patient and provides comprehensive treatment programs with vaccine and cell therapies at the most modern facility of the largest private hospital network of 22 hospitals in Mexico. The hospital meets the highest U.S. and international standards and is the only full-service hospital in Mexico offering integrative medicine.
Joseph Momot commenced the non-toxic Issels Integrative Immunotherapy for his chemotherapy-resistant hepatocellular carcinoma in June 2010. Within 4 weeks of exclusive immunotherapy, his total bilirubin decreased from 20.3 to 5.2 mg/dl, then to 2.1 mg/dl the next month. His jaundice and edemas disappeared; he regained his energy and felt like a "new person."
Please see the video of Joseph Momot at the top right of the Multimedia News Release.
Carl Swanberg shares his remarkable results from using solely Issels immunobiologic core treatment for his hepatocellular cancer, hepatitis C, and liver cirrhosis. He arrived at the Issels out-patient clinic in November 2004 with 3 months to live. His AFP tumor marker of 4,500 dramatically decreased to 124 within 3 weeks, and to 60 after a year.
The Issels immunobiologic core treatment is available at the Issels U.S. out-patient facility, where patients can also receive genetically-tested advanced targeted cancer therapies.
Please see the video of Carl Swanberg at the top right of the Multimedia News Release.
Visit the Issels website www.issels.com to learn more about the Issels treatment programs and facilities, or watch more videos of patient testimonials.